[{"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 987100, "exercisedValue": 0, "unexercisedValue": 13998124}, {"maxAge": 1, "name": "Mr. Gregory S. Zante CPA, CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 655000, "exercisedValue": 0, "unexercisedValue": 59203}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 59, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 670000, "exercisedValue": 0, "unexercisedValue": 2005070}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 59, "title": "Vice President of Finance & Administration", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 375333, "exercisedValue": 0, "unexercisedValue": 490518}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Senior Vice President of Pharmaceutical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 34.94, "open": 34.56, "dayLow": 34.19, "dayHigh": 35.96, "regularMarketPreviousClose": 34.94, "regularMarketOpen": 34.56, "regularMarketDayLow": 34.19, "regularMarketDayHigh": 35.96, "beta": 0.994, "forwardPE": -24.369913, "volume": 3453648, "regularMarketVolume": 3453648, "averageVolume": 4486696, "averageVolume10days": 4747090, "averageDailyVolume10Day": 4747090, "bid": 34.4, "ask": 34.63, "bidSize": 1200, "askSize": 1100, "marketCap": 3844541952, "fiftyTwoWeekLow": 21.26, "fiftyTwoWeekHigh": 99.41, "fiftyDayAverage": 45.3766, "twoHundredDayAverage": 58.14935, "currency": "USD", "enterpriseValue": 2915350272, "floatShares": 105458936, "sharesOutstanding": 111436000, "sharesShort": 19468391, "sharesShortPriorMonth": 18071399, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.17469999, "heldPercentInsiders": 0.027190002, "heldPercentInstitutions": 0.74528, "shortRatio": 5.43, "shortPercentOfFloat": 0.2347, "impliedSharesOutstanding": 111436000, "bookValue": 8.179, "priceToBook": 4.2181196, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -99151000, "trailingEps": -0.94, "forwardEps": -1.51, "52WeekChange": 0.4429109, "SandP52WeekChange": 0.23809385, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VKTX", "underlyingSymbol": "VKTX", "shortName": "Viking Therapeutics, Inc.", "longName": "Viking Therapeutics, Inc.", "firstTradeDateEpochUtc": 1430227800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e658b393-1b8d-3e3b-b1d5-0d5bdf22cb43", "messageBoardId": "finmb_246791410", "gmtOffSetMilliseconds": -18000000, "currentPrice": 34.5, "targetHighPrice": 164.0, "targetLowPrice": 74.0, "targetMeanPrice": 110.0, "targetMedianPrice": 110.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 15, "totalCash": 930440000, "totalCashPerShare": 8.35, "totalDebt": 1235000, "quickRatio": 36.225, "currentRatio": 36.467, "debtToEquity": 0.135, "returnOnAssets": -0.12681, "returnOnEquity": -0.15496, "freeCashflow": -44290000, "operatingCashflow": -74249000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]